Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 10/20 | 0.38 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.38 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440869 | 0.76 | DYRK1A (0.49) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL30512173 | 0.74 | DYRK1A (0.47) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL26355235 | 0.74 | DYRK1A (0.47) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL2750457 | 0.74 | TGFBR1 (0.51) | DYRK1ASCN5ATGFBR1PCSK9PIK3CD | |
| SCHEMBL4162933 | 0.74 | DYRK1A (0.47) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL4789377 | 0.74 | DYRK1A (0.47) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL5435761 | 0.74 | DYRK1A (0.61) | DYRK1APDE10ASCN5ATGFBR1PCSK9 | |
| SCHEMBL1348265 | 0.74 | SCN5A (0.60) | DYRK1ASCN5ATGFBR1PIK3CD | |
| SCHEMBL402164 | 0.72 | DYRK1A (0.46) | DYRK1ASCN5ATGFBR1PCSK9PIK3CD | |
| SCHEMBL30603240 | 0.72 | DYRK1A (0.50) | DYRK1APDE10ASCN5ATGFBR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163445-B | Larotinib intermediate and preparation method thereof | 重庆医科大学 | 2023-06-20 | — | — | CN | claimed |
| CN-114163445-A | Raatinib intermediate and preparation method thereof | 重庆医科大学 | 2022-03-11 | — | — | CN | claimed |
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2022-03-08 | — | — | US | claimed |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2021-01-07 | — | — | US | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260049086-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-20260028337-A1 | COMPOUND FOR INHIBITING IRAK4 ACTIVITY AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1562925-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004043940-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | DYRK1A 1528/4885PDE10A 2273/4885SCN5A 56/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | DYRK1A 3248/4885PDE10A 626/4885SCN5A 1519/4885 |
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | DYRK1A 3789/4885PDE10A 1857/4885SCN5A 1846/4885 |
| US-20260049086-A1 | CDK9 INHIBITORS | CDK9, CDK6, CDK19 | DYRK1A 1185/4885PDE10A 2285/4885SCN5A 2366/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | DYRK1A 3376/4885PDE10A 3514/4885SCN5A 2071/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | DYRK1A 1894/4885PDE10A 1859/4885SCN5A 389/4885 |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | DYRK1A 3789/4885PDE10A 1857/4885SCN5A 1846/4885 |
| US-20260028337-A1 | COMPOUND FOR INHIBITING IRAK4 ACTIVITY AND USE THEREOF | IRAK4, IRAK1, IRAK3 | DYRK1A 520/4885PDE10A 3785/4885SCN5A 2478/4885 |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DYRK1A 2175/4885PDE10A 2560/4885SCN5A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.